GSK’s Agentic Pharmacovigilance Test Pushes QA Into Live Evidence Chains

AI agents are moving pharmacovigilance and other regulated workflows toward continuous, auditable evidence generation, raising the bar for QA control and traceability.

Updated

What is this trend?

Agentic pharmacovigilance is turning QA into a live evidence chain, where AI-driven case work must produce traceable, reviewable records as it runs.

  • AI agents are handling PV tasks, but humans still approve regulated decisions.
  • QA shifts from checking outputs to verifying provenance, logs, and decision trails.
  • Controls must survive workflow changes, model updates, and exception paths.
  • Auditability is becoming a built-in product feature, not a post-hoc review step.
  • Evidence integrity now matters across AI, cloud, lab, and regulated record systems.

What’s the latest?

GSK’s reported test of an AI-agent pharmacovigilance model is the clearest sign of the shift: roughly 40 specialized agents are being used to handle case intake, coding, checks, signal evaluation, and

How it developed

  1. Agentic QA Goes Autonomous, and Validation Becomes Continuous Evidence Governance
  2. Agentic QA, Embedded Controls, and Continuous Risk Governance
  3. Agentic QA in pharma, Kubernetes test orchestration, and the rise of container-savvy testers

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by seniority.

Stay ahead in Quality Assurance / Quality Control

Get the weekly Quality Assurance / Quality Control brief in your inbox — the developments, what they mean by seniority, and what to do next.